|
|
||||||||
Department of Microbiology and Immunology and Division of Bacterial Toxin, Research Center for Infectious Disease, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| Abstract |
|---|
|
|
|---|
B activation by preventing
loss of I
B-
and -
. Furthermore, SA blocked phosphorylation of
extracellular signal-regulated kinase 1/2 (Erk1/2), but not
phosphorylation of p38 and c-Jun N-terminal kinase. SA treatment
resulted in the disappearance of Raf-1, suggesting that it might cause
the inhibition of the Erk1/2 mitogen-activated protein (MAP) kinase
pathway. The SA-mediated loss of Raf-1 also abolished LPS-induced
NF-
B activation as well as the Erk1/2 pathway. The dominant negative
mutant of MAP kinase kinase 1 inhibited both NO production and NF-
B
activation in LPS-stimulated RAW cells. Taken together, these results
indicate that the inhibitory action of SA on NO production in
LPS-stimulated macrophages might be due to abrogation of inducible NO
synthase induction, and it might be closely related to inactivation of
the NF-
B and Erk1/2 MAP kinase pathways through loss of
Raf-1. | Introduction |
|---|
|
|
|---|
B (8, 9, 10) and
mitogen-activated protein (MAP) kinases (11, 12, 13, 14). NO
produced in large quantities following induction of iNOS by LPS in
macrophages might play a critical role in endotoxin-induced tissue
injury (15, 16). In fact, we have demonstrated that the
expression of iNOS and peroxynitrite-induced nitrotyrosine was detected
mainly around blood vessels in endotoxin-induced hepatic injury as an
experimental endotoxic shock model (17). Sodium arsenite
(SA), a standard inducer of heat shock response, is reported to prevent
LPS-induced endothelial cell injury (18, 19, 20). Recently, we
have also reported that SA inhibits LPS-induced bovine endothelial cell
injury (21). Therefore, it was of particular interest to
determine whether SA affected the production of harmful NO in
LPS-stimulated macrophages. In the present study we investigated the
effect of SA on LPS-induced NO production in the murine macrophage cell
line, RAW 267.4. Herein we describe that SA inhibits LPS-induced NO
production by down-regulating extracellular signal-regulated kinase 1/2
(Erk1/2) MAP kinase and NF-
B pathways through the loss of Raf-1. | Materials and Methods |
|---|
|
|
|---|
LPS from Escherichia coli O55:B5 and SA were obtained from Sigma (St. Louis, MO) and Wako Pure Chemicals (Osaka, Japan), respectively. Geldanamycin and pyrrolidine dithiocarbamate (PDTC), purchased from Calbiochem (San Diego, CA), were dissolved to a 1-mM stock solution, which was further diluted in the culture medium for the experiments. The dominant negative mutant of MAP kinase kinase 1 (MEKK1) was supplied by Dr. J. D. Lee (The Scripps Research Institute, La Jolla, CA).
Cell culture
The murine macrophage cell line, RAW 267.4, obtained from the Health Science Resource Bank (Tokyo, Japan), was maintained in RPMI 1640 medium (Sigma) containing 5% heat-inactivated FCS (Life Technologies, Grand Island, NY) at 37°C with 5% CO2. The cells were washed gently with HBSS (Sigma) and removed from the flasks. The cells were suspended in a 35-mm plastic dish, 96-well plate, or 12-well plate for the experiments.
Pretreatment with SA, geldanamycin, and PDTC
RAW cells were cultured with various concentrations of SA for 90 min, with geldanamycin (3 µM) for 16 h, or with PDTC (100 µM) for 90 min at 37°C. The pretreated cells were washed before use.
Determination of nitrite concentration
NO was measured as its end product, nitrite, using Griess reagent as described previously (22). Culture supernatants (50 µl) were mixed with 100 µl of Griess reagent (1% sulfanilamide, 0.1% N-(1-napthyl)-ethylenediamine dihydrochloride, and 2.5% orthophosphoric acid). After 10 min absorbance at 570 nm was measured in a microplate ELISA reader. The concentration of nitrite in the culture supernatant was determined with reference to a sodium nitrite standard curve. Data represent the mean of triplicate determinations ± SD. Correction of the NO concentration was not performed because there was no significant difference in the cell number and viability of each experiment.
Laser flow cytometric analysis of CD14 expression, LPS binding, and phagocytosis
RAW cells were pretreated with SA (10 µM) for 90 min. Untreated and SA-pretreated RAW cells were incubated with a 1:200 dilution of FITC-conjugated anti-mouse CD14 Ab (PharMingen, San Diego, CA) or 1 µg/ml of FITC-conjugated LPS (Sigma) at 4°C for 1 h. Phagocytic activity was estimated by first incubating the cells with 1 µl/ml of FITC-labeled beads (Polysciences, Warrington, PA) at 37°C for 1 h. The cells were then washed with PBS and suspended in PBS. The fluorescence intensity was analyzed by a laser flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA).
Immunoblotting
Untreated and SA-pretreated RAW cells were seeded in 35-mm
plastic dishes (4 x 105 cells/dish) and
incubated with LPS for 1 or 8 h. Cells were lysed in the lysis
buffer (0.5 M Tris-HCl, 4% SDS, and 2-ME) and boiled for 5 min at
100°C. Aliquots (20 µg/lane) containing equal amounts of protein
were electrophoresed under reducing conditions in a 420% gradient
polyacrylamide gel and transferred to a polyvinylidene difluoride
membrane filter. The membranes were treated with 5% BSA for 1 h
to block nonspecific binding, rinsed, and incubated with a panel of
rabbit polyclonal Abs against 90-kDa heat shock protein (HSP90;
StressGene, Victoria, Canada); iNOS (Upstate Biotechnology, Lake
Placid, NY); and Raf-1, I
B-
and -
, Erk1/2, phospho-Erk1/2,
p38, phospho-p38, phospho-c-Jun N-terminal kinase/stress-activated
protein kinase (phospho-JNK/SAPK), and JNK/SAPK (New England Biolabs,
Beverly, MA) for 1 h. The membranes were then treated with a
1:3000 dilution of HRP-conjugated protein G for 1 h. Immune
complexes were detected with an enhanced chemiluminescence substrate
(New England Nuclear, Boston, MA) and exposed to Kodak XAR x-ray film
(Eastman Kodak, Rochester, NY).
Luciferase reporter gene assay for NF-
B activation
RAW cells (3 x 105/1 ml) were plated
in 35-mm plastic dishes. On the following day the cells were
transfected with 0.5 µg of pNF-
B-Luc plasmid (a luciferase
reporter gene driven by five tandem repeats of NF-
B, PathDetect
System, Stratagene, La Jolla, CA) and 0.5 µg of pCMV-
-gal plasmid
(Life Technologies) by the lipofectin method (Life Technologies). The
transfected cells were pretreated with SA, geldanamycin, or PDTC for a
specified time followed by treatment with LPS (1 µg/ml) for 8 h.
The cells were lysed using the lysis reagent from Promega (Madison, WI)
before measurement of luciferase activity. The luciferase activity was
determined on cell lysates with a luminometer.
-Galactosidase
activity was used to normalize transfection efficiencies. All bar
diagrams are shown as the mean ± SD for two experiments in which
each transfection was performed in duplicate.
Transfection with antisense oligodeoxynucleotides and the dominant negative MEKK1 mutant
An antisense oligonucleotide to Raf-1 (ATGCATTCTGCCCCCAAGGA) and
a control mismatch antisense oligonucleotide (ATGCAGTCTTCCACCACGGA)
were synthesized by Rikaken (Nagoya, Japan). RAW cells, at
50%
confluence, were transfected with either the antisense oligonucleotide
to Raf-1 or the control mismatch antisense oligonucleotide (300 nM)
using the lipofectin method (Life Technologies) for 8 h. After
8 h, fresh RPMI 1640 containing 10% FCS was added, and the cells
were incubated for an additional 24 h before the addition of LPS.
The dominant negative MEKK1 mutant was transfected under similar
conditions.
| Results |
|---|
|
|
|---|
The effect of SA pretreatment on LPS-induced NO production in RAW
cells was examined (Fig. 1
A).
RAW cells were pretreated with various concentrations of SA for 90 min,
followed by a 24-h incubation with LPS (1 µg/ml). SA pretreatment
reduced LPS-induced NO production in a dose-dependent manner, although
SA pretreatment at a concentration range of 0.5100 µM did not
affect spontaneous NO production in RAW cells. SA pretreatment also
inhibited NO production in response to a higher concentration of LPS
(10 µg/ml; data not shown). In addition, there was no significant
difference in viability or phagocytic function between SA-pretreated
and control untreated RAW cells (data not shown).
|
The effect of SA post-treatment on LPS-induced NO production was
examined (Fig. 1
C). RAW cells were incubated with LPS (1
µg/ml) for various times, followed by the addition of SA (10 µM) to
the cultures. The addition of SA to the cultures of RAW cells
pretreated with LPS for 3 h resulted in the inhibition of NO
production. However, SA did not inhibit NO production in cells
pretreated with LPS (1 µg/ml) for 4 h or more.
SA inhibits the expression of iNOS protein in LPS-stimulated RAW cells
Because SA inhibited LPS-induced NO production, the expression of
iNOS protein in response to LPS (1 µg/ml) was studied in
SA-pretreated RAW cells by immunoblotting using an anti-iNOS Ab
(Fig. 2
). The iNOS protein was readily
detected in LPS-stimulated RAW cells. However, pretreatment of RAW
cells with SA abrogated the appearance of iNOS in response to LPS. The
absence of induction of iNOS protein in SA-pretreated cells was also
confirmed by immunofluorescence staining with an anti-iNOS
Ab.
|
To determine the mechanism of SA inhibition of NO production and iNOS expression in LPS-stimulated RAW cells, we studied the binding of FITC-labeled LPS, the level of cell surface CD14 expression, and the phagocytic activity in control untreated RAW cells and in SA-pretreated RAW cells. Laser flow cytometric analysis demonstrated that there was no significant difference in the binding of FITC-labeled LPS, the level of CD14 expression, or the phagocytic activity between SA-pretreated or control untreated RAW cells (data not shown). This result suggests that SA might affect the intracellular signal transduction of LPS binding to the nucleus or to the effector system in NO production.
SA inhibits the activation of NF-
B in LPS-stimulated RAW
cells
It has been reported that the activation of NF-
B is involved in
LPS-induced NO production in RAW cells (8, 9, 10). Therefore,
we tested the effect of SA on LPS-induced NF-
B activation using a
luciferase reporter gene assay (Fig. 3
A). LPS markedly enhanced
reporter gene activity in untreated RAW cells indicating NF-
B
activation. Conversely, pretreatment of cells with SA completely
abrogated the enhancement of NF-
B-dependent reporter gene activity
induced by LPS. PDTC, a known inhibitor of NF-
B, was confirmed to
inhibit LPS-induced NF-
B-dependent reporter gene activity.
|
B-
and -
expression was examined to
clarify the inhibitory action of SA on LPS-induced NF-
B activation
(Fig. 3
B-
and -
protein was
studied in RAW cells following exposure to LPS with or without SA
pretreatment by immunoblotting. Although LPS caused marked reduction in
the expression of I
B-
and -
in untreated RAW cells, LPS did
not alter the expression of I
B-
and -
in SA-pretreated cells.
This suggests that pretreatment with SA inhibits LPS-induced loss of
both I
B-
and -
. SA inhibits the phosphorylation of Erk1/2, but not p38 or JNK/SAPK, in LPS-stimulated RAW cells
LPS is known to activate a series of MAP kinases, such as Erk1/2,
p38, and JNK/SAPK, in macrophages (11, 12, 13, 14). These signal
pathways may be involved in LPS-induced NO production in RAW cells.
Therefore, the effect of SA on the activation of these MAP kinase
pathways was examined by immunoblotting using anti-phospho-MAP
kinase Abs (Fig. 4
). LPS clearly induced
phosphorylated forms of Erk1/2, p38, and JNK/SAPK in untreated RAW
cells. However, in SA-pretreated cells, although LPS induced the
phosphorylation of p38 and JNK/SAPK, it did not induce the
phosphorylation of Erk1/2. SA did not affect the basal level of Erk1/2
expression in RAW cells, but inhibited the phosphorylation of Erk1/2.
This suggests that SA may reduce LPS-induced NO production by
inhibiting the phosphorylation of the Erk1/2 MAP kinase pathway. It is
supported by the finding that PD98059 (20 µM), a MEK inhibitor,
inhibits LPS-induced NO production in RAW cells (
50%
inhibition).
|
We have demonstrated that SA pretreatment abolishes the
phosphorylation of Erk1/2 without affecting the basal level of Erk1/2.
Based on the fact that Raf-1 plays a critical role in phosphorylation
of Erk1/2 via MEK1/2 (23), we examined the effect of SA on
the expression level of Raf-1 in RAW cells by immunoblotting (Fig. 5
). The level of Raf-1 protein was not
significantly altered in RAW cells regardless of the presence of LPS.
Strikingly, Raf-1 protein was not detected in SA-pretreated RAW cells
(Fig. 5
A). SA-mediated loss of Raf-1 was detected 5 min
after SA treatment (Fig. 5
B). Treatment of RAW cells with SA
resulted in the disappearance of Raf-1 protein, thereby inhibiting
LPS-induced Raf-1-dependent phosphorylation of Erk1/2. Further, we
examined whether LPS activated Raf-1 in a Ras-dependent or independent
manner. FPTII, a specific inhibitor of Ras, did not inhibit LPS-induced
NO production (data not shown), suggesting that LPS activated Raf-1 in
a Ras-independent manner.
|
We have shown that SA treatment of RAW cells results in the
disappearance of Raf-1 protein. Three components of the MAP kinase
signaling system (Src, Raf, and Mek) are found in association with
HSP90, and Raf-1 is stabilized by forming heteromeric complexes with
HSP90 (23). Further, NO production is known to be mediated
in part through HSP90 signaling (24). Therefore, it was of
interest to determine whether SA affects the formation of Raf-1/HSP90
heteromeric complexes (Fig. 6
). The
effect of SA on the expression of HSP90 in RAW cells was examined by
immunoblotting using an anti-HSP90 Ab. The expression of HSP90 was
not significantly affected by treatment with LPS or SA alone or by
treatment with SA followed by LPS, suggesting no alteration in HSP90
expression. To clarify the role of Raf-1/HSP90 heteromeric complexes in
LPS-induced NO production in RAW cells, the effect of geldanamycin,
which is known to destabilize the preformed heteromeric complexes, on
LPS-induced NO production was examined (Fig. 7
). The addition of geldanamycin to RAW
cells did not affect spontaneous NO production. However, geldanamycin
clearly reduced NO production in LPS-stimulated RAW cells, suggesting
that the destabilization of Raf-1/HSP90 heteromeric complexes is likely
to reduce LPS-induced NO production. In addition, PDTC, an inhibitor of
NF-
B, significantly inhibited LPS-induced NO production, suggesting
the participation of NF-
B.
|
|
B activation
The effect of the Raf-1 antisense oligonucleotide on LPS-induced
NO production was studied (Fig. 8
).
Introduction of the Raf-1 antisense oligonucleotide into RAW cells
significantly suppressed the expression of Raf-1 protein (Fig. 8
A). Furthermore, it blocked LPS-induced phosphorylation of
Erk1/2 (Fig. 8
B). The effect of the Raf-1 antisense
oligonucleotide on LPS-induced NO production was examined (Fig. 9
). LPS-induced NO production was
significantly inhibited in RAW cells transfected with the Raf-1
antisense oligonucleotide (Fig. 9
A), but not with the
mismatch control. Interestingly, transfection of the Raf-1 antisense
oligonucleotide also inhibited NF-
B activation as well as Erk1/2
phosphorylation in LPS-stimulated RAW cells (Fig. 9
B). This
strongly suggests that Raf-1 plays a key role in LPS-induced NO
production.
|
|
B
We found that Raf-1 antisense oligonucleotide surprisingly
inhibited NF-
B activation in LPS-stimulated RAW cells. Therefore,
the effect of geldanamycin, which is known to destabilize the
Raf-1/HSP90 heteromeric complexes, on LPS-induced NF-
B activation
was examined using the luciferase reporter gene assay (Fig. 10
). Geldanamycin blocked the
LPS-induced enhancement of NF-
B-dependent reporter gene activity.
Therefore, it appears that destabilization of Raf-1/HSP90 by
geldanamycin causes the inhibition of LPS-induced NF-
B
activation.
|
B
activation and NO production in LPS-stimulated RAW cells
Raf-1 has been recently reported to activate MEKK1
(25) and result in NF-
B translocation
(26). Thus, the SA-mediated loss of Raf-1 protein may
abolish Raf-1-mediated MEKK1 activation, leading to a loss of NF-
B
induction. The effect of a dominant negative MEKK1 mutant on NO
production and NF-
B activation in LPS-stimulated RAW cells was
studied (Fig. 11
). Transfection of RAW
cells with the dominant negative MEKK1 mutant did not affect the
constitutive expression of Raf-1 (data not shown), suggesting that
Raf-1 is the upstream activator of MEKK1. As shown in Fig. 11
A, transfection of the dominant negative MEKK1 mutant
resulted in the striking inhibition of LPS-induced NF-
B activation
(50% reduction). LPS-induced NO production was also inhibited in cells
transfected with the dominant negative MEKK1 mutant (Fig. 11
B). The inhibition by the dominant negative MEKK1 mutant
was less than that observed by treatment with SA.
|
| Discussion |
|---|
|
|
|---|
B and Erk1/2 MAP kinase
pathways, but not p38 or JNK MAP kinase pathways. In particular, the
inhibition of NF-
B activation by SA is important for the suppression
of LPS-induced iNOS expression, because the activation of NF-
B plays
a critical role in the expression of iNOS in LPS-stimulated macrophages
(8, 9, 10). Furthermore, we demonstrate that SA
down-regulates the Erk1/2 MAP kinase signal pathway in which Raf-1
activates MEK1/2, which, in turn, activates the Erk1/2 kinases. There
are several reports that iNOS expression in LPS-stimulated macrophages
is mediated by the Erk1/2 MAP kinase pathway (11, 12, 13). We
also demonstrate the inhibition of LPS-induced NO production by a MEK
inhibitor, PD98059. This strongly suggests that the inhibitory action
of SA on LPS-induced NO production is due to abrogation of iNOS
induction through the down-regulation of NF-
B and/or Erk1/2 MAP
kinase signal pathways.
Raf-1 is a component of the Erk1/2 MAP kinase signal system
(27), suggesting that loss of Raf-1 causes the impairment
of Erk signaling pathway. However, the loss of Raf-1 by antisense
oligonucleotide, geldanamycin, and SA also down-regulated LPS-induced
NF-
B activation. How could the Raf-1 molecule lead to the activation
of NF-
B? Recently, Bauman et al. (26) have reported
that Raf-1 mediates the activation of NF-
B through MEKK1. This
evidence may elucidate our finding that SA-mediated Raf-1 loss resulted
in the down-regulation of NF-
B activation and inhibited the
expression of iNOS in LPS-stimulated RAW cells. In fact, we demonstrate
that the dominant negative mutant of MEKK1 down-regulates LPS-induced
NF-
B activation and NO production without affecting Raf-1
expression. Taken together, these results show that SA causes the loss
of Raf-1, resulting in the down-regulation of MEKK1 activity and the
subsequent inhibition of NF-
B activation. Thus, the loss of
Raf-1 reduced NO production in LPS-stimulated RAW cells through the
inhibition of NF-
B and Erk activity, demonstrating that Raf-1 plays
a critical role in LPS-induced NO production in macrophages. In
addition, SA is reported to inhibit NF-
B-mediated gene transcription
by blocking I
B kinase activity and I
B-
phosphorylation and
degradation (28).
SA induced the disappearance of Raf-1, which is the immediate upstream activator of MEK1/2 and the upstream activator of Erk1/2 MAP kinase signal pathway. Therefore, it is reasonable that SA abrogates the Erk1/2 MAP kinase pathway through the loss of Raf-1 in LPS-stimulated RAW cells. Of particular interest are a series of recent reports implicating HSP90 and its associated proteins in signal transduction of macrophage activation (24, 25). Raf-1 protein exists in native complexes with HSP90 that can be formed in vitro by reticulocyte lysate, and its catalytic domain is sufficient for HSP90 binding (29, 30). Based on the fact that geldanamycin, which binds to HSP90 and leads to a block in Raf-1/HSP90 heteromeric complex assembly (31, 32), significantly inhibits LPS-induced NO production in RAW cells, the Raf-1/HSP90 heteromeric complexes are likely to participate in iNOS induction in LPS-stimulated RAW cells. It was shown that SA inhibits the Erk1/2 MAP kinase pathway by the loss of Raf-1 without affecting the expression of HSP90. The critical role of Raf-1 is also supported by the results showing that LPS-induced NO production was significantly inhibited in RAW cells transfected with the Raf-1 antisense oligonucleotide. Recently, Byrd et al. (24) reported that HSP90 can bind LPS and mediates macrophage activation by LPS. However, the exact action of LPS on Raf-1/HSP90 complex has not yet been clarified.
A series of signaling pathways, including NF-
B, Erk1/2 kinase, p38
MAP kinase, and JNK/SAPK MAP kinase pathways, is involved in the
induction of iNOS in LPS-stimulated macrophages. The present study
demonstrates an intimate cross-talk between the NF-
B and Erk1/2
pathways in iNOS expression. This is supported by several reports that
NF-
B transcriptional activity is controlled by Erk1/2 MAP kinase
(33, 34, 35, 36). In addition, the signaling pathways with p38 MAP
kinase and SAPK/JNK MAP kinase are reported to be involved in
LPS-induced iNOS expression (13, 37). Although SA did not
inhibit the phosphorylation of p38 and JNK/SAPK MAP kinases, SA
completely inhibited NO production in LPS-stimulated RAW cells. It did
not exclude the participation of p38 and JNK/SAPK in LPS-induced NO
production. Thus, NO production in LPS-stimulated macrophages is
regulated through a complex signaling system via the NF-
B and MAP
kinase pathways.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Takashi Yokochi, Department of Microbiology and Immunology, Aichi Medical University, Nagakute, Aichi 480-1195, Japan. ![]()
3 Abbreviations used in this paper: NOS, NO synthase; SA, sodium arsenite; Erk1/2, extracellular signal-regulated kinase 1/2; JNK/SAPK, c-Jun-N-terminal kinase/stress-activated protein kinase; MAP, mitogen-activated protein; MEKK1, MAP kinase kinase 1; iNOS, inducible isoform of NO synthase; PDTC, pyrrolidine dithiocarbamate; HSP90, 90-kDa heat shock protein. ![]()
Received for publication June 27, 2000. Accepted for publication November 15, 2000.
| References |
|---|
|
|
|---|
and LPS. J. Biol. Chem. 268:1908.
B activation prevents iNOS synthase expression and systemic hypotension in a rat model of septic shock. J. Immunol. 159:3976.[Abstract]
B. Immunol. Today 19:80.[Medline]
B activation. J. Biol. Chem. 273:15301.
accumulation in murine macrophages stimulated with LPS and IFN-
. J. Infect. Dis. 179:939.[Medline]
B by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc. Natl. Acad. Sci. USA 97:4615.
B-mediated gene transcription by blocking I
B kinase activity and I
B
phosphorylation and degradation. Arch. Biochem. Biophys. 377:204.[Medline]
B via T cell receptor requires a Raf kinase and C a2+ influx. J. Immunol. 157:5277.[Abstract]
B. J. Biol. Chem. 274:27981.
B-dependent IL-6 expression in human monocytes. J. Immunol. 162:4893.
. Biochem. Biophys. Res. Commun. 253:790.[Medline]This article has been cited by other articles:
![]() |
A. S. M. Noman, N. Koide, F. Hassan, I. I.-E-Khuda, J. Dagvadorj, G. Tumurkhuu, S. Islam, Y. Naiki, T. Yoshida, and T. Yokochi Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} production via down-regulation of MyD88 expression Innate Immunity, February 1, 2009; 15(1): 33 - 41. [Abstract] [PDF] |
||||
![]() |
H. J. Kim, K. Tsoyi, J. M. Heo, Y. J. Kang, M. K. Park, Y. S. Lee, J. H. Lee, H. G. Seo, H. S. Yun-Choi, and K. C. Chang Regulation of Lipopolysaccharide-Induced Inducible Nitric-Oxide Synthase Expression through the Nuclear Factor-{kappa}B Pathway and Interferon-beta/Tyrosine Kinase 2/Janus Tyrosine Kinase 2-Signal Transducer and Activator of Transcription-1 Signaling Cascades by 2-Naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a New Synthetic Isoquinoline Alkaloid J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 782 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan, and C. Huang Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells J. Biol. Chem., August 25, 2006; 281(34): 24405 - 24413. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sanchez-Tillo, M. Comalada, C. Farrera, A. F. Valledor, J. Lloberas, and A. Celada Macrophage-Colony-Stimulating Factor-Induced Proliferation and Lipopolysaccharide-Dependent Activation of Macrophages Requires Raf-1 Phosphorylation to Induce Mitogen Kinase Phosphatase-1 Expression. J. Immunol., June 1, 2006; 176(11): 6594 - 6602. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Farhana, M. I. Dawson, and J. A. Fontana Apoptosis Induction by a Novel Retinoid-Related Molecule Requires Nuclear Factor-{kappa}B Activation Cancer Res., June 1, 2005; 65(11): 4909 - 4917. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jaramillo, P. H. Naccache, and M. Olivier Monosodium Urate Crystals Synergize with IFN-{gamma} to Generate Macrophage Nitric Oxide: Involvement of Extracellular Signal-Regulated Kinase 1/2 and NF-{kappa}B J. Immunol., May 1, 2004; 172(9): 5734 - 5742. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Darieva, E. B. Lasunskaia, M. N. N. Campos, T. L. Kipnis, and W. D. da Silva Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-{kappa}B-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding J. Leukoc. Biol., April 1, 2004; 75(4): 689 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Caivano, C. Rodriguez, P. Cohen, and S. Alemany 15-Deoxy-{Delta}12,14-prostaglandin J2 Regulates Endogenous Cot MAPK Kinase Kinase 1 Activity Induced by Lipopolysaccharide J. Biol. Chem., December 26, 2003; 278(52): 52124 - 52130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jaramillo, D. C. Gowda, D. Radzioch, and M. Olivier Hemozoin Increases IFN-{gamma}-Inducible Macrophage Nitric Oxide Generation Through Extracellular Signal-Regulated Kinase- and NF-{kappa}B-Dependent Pathways J. Immunol., October 15, 2003; 171(8): 4243 - 4253. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Tong, G. Singh, and A. J. Rainbow Sustained Activation of the Extracellular Signal-regulated Kinase Pathway Protects Cells from Photofrin-mediated Photodynamic Therapy Cancer Res., October 1, 2002; 62(19): 5528 - 5535. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-H. Yih, K. Peck, and T.-C. Lee Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment Carcinogenesis, May 1, 2002; 23(5): 867 - 876. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Pathak and T. Yi Sodium Stibogluconate Is a Potent Inhibitor of Protein Tyrosine Phosphatases and Augments Cytokine Responses in Hemopoietic Cell Lines J. Immunol., September 15, 2001; 167(6): 3391 - 3397. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |